New diabetes medication gets green light
Note: this article is provided by ONU Healthwise Pharmacy.
The US Food and Drug Administration (FDA) has approved a new diabetes medication.
This new approval is found under the names Rybelsus (brand name) and semaglutide (active ingredient). The FDA approved semaglutide to treat adults with type 2 diabetes in combination with diet and exercise.
This new drug is available in tablet form and is to be taken once a day. It is to be taken at least 30 minutes before you consume any food, beverage or other medication for the day. Rybelsus needs to be taken with no more than 4 ounces of plain water.
Because it does not need to be injected like other diabetes drugs, this new approval offers those with diabetes a new treatment option. Semaglutide is the first in its class of medications (GLP-1 drugs) that does not need to be injected.
“Before this approval, patients did not have an oral GLP1 option to treat their type 2 diabetes, and now patients will have a new option for treating type 2 diabetes without injections,” said Dr. Lisa Yanoff, acting director of the FDA's Division of Metabolism and Endocrinology Products, in a press release.
Common side effects of semaglutide may include nausea, diarrhea, vomiting, decreased appetite, indigestion (that can lead to feeling full, burping and discomfort) and constipation.
This medication can slow digestion. Speak with your health care provider about all of the medications you are taking before starting this medication.
Rybelsus comes with a boxed warning regarding an increased risk of thyroid c-cell tumors.
Semaglutide is not for those with type 1 diabetes or diabetic ketoacidosis. It is not recommended as the first choice when treating diabetes.
Serious side effects may include inflammation of the pancreas, damage to the retina, low blood sugar and acute kidney injury.
The FDA granted approval of this medication to Novo Nordisk.
Stories Posted This Week
Saturday, April 26, 2025
Friday, April 25, 2025
Thursday, April 24, 2025
- Blanchard Valley Health Foundation welcomes Sapp as Chief Development Officer
- LEO Club invitation to 5K and 1-mile walk & stroll
- Memorial bench and tree planting at Village Arboretum
- Bluffton Beavers sports roundup, April 16-22
- Pirate baseball loss vs. Fort Jennings
- Alan Garmatter is new CNB Chief Credit Officer
- Parks & Recreation Committee meets April 25
- Bad Dreams: Health implications
Wednesday, April 23, 2025
Tuesday, April 22, 2025
Monday, April 21, 2025
- ONU theater students give voice to the Ukrainian people
- Permits will be needed for overnight parking on Spring St.
- April 26 Easter for Kids event
- Anabaptist choral concert on April 27
- April 23 landscaping night at the Bluffton Sportsmen's Club-LE&W Depot
- Upcoming BPL events, April 21-26
- Marc Augsburger is 2025 Outstanding Alumni from Rhodes State College
- Pirate girls win O-G Gold track meet, Bluffton boys 2nd